Trending...
- CCHR Says New OIG Report Raises Concerns about Drugging Elderly with Antipsychotics
- Spokane Launches 'Summer of Soccer' Community Campaign
- Spokane: Abor Day Celebration 2026
STUART, Fla., April 19, 2024 ~ Stuart Therapeutics, Inc., a clinical-stage ophthalmic biopharmaceutical company, is making strides in the development of therapies for various eye disorders. The company's President and CEO, Eric Schlumpf, will be presenting their latest research results at two upcoming meetings in early May.
On Friday, May 3rd, Schlumpf will be speaking at the Dry Horizons Symposium, co-sponsored by Ora, Inc. His presentation will focus on Stuart Therapeutics' innovative dry eye disease program, which is currently in a Phase 3 trial. The following day, Saturday May 4th, he will be presenting the company's latest pre-clinical results in retinitis pigmentosa and exudative retinal indications at the Ophthalmology Innovation Source (OIS) Retina Meeting.
Both of these meetings will take place at the Four Seasons Hotel in Seattle, Washington. This provides an opportunity for Stuart Therapeutics to showcase their groundbreaking research to a wide audience of industry professionals.
More on Washingtoner
In addition to Schlumpf's presentations, members of Stuart Therapeutics' R&D team have also co-authored a poster presentation that will be presented by researchers from the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting from May 5-9, 2024. The poster presentation titled "Scleral collagen remodeling and repair assessed in intact eyes through Second Harmonic Generation" focuses on work done at the University of Rochester using Stuart Therapeutics' proprietary collagen mimetic peptide platform. This research aims to understand its effectiveness in reversing scleral collagen disruption in the eye, which is believed to contribute to myopia.
The study authors include Aldo Tecse, Kaitlin Wozniak, James German, Alex McMullen, Mark Buckley, Robert Baratta, Eric Schlumpf, Brian J. Del Buono, Michael Telias and Susana Marcos. This collaboration between Stuart Therapeutics and the University of Rochester highlights the company's commitment to advancing the field of ophthalmology and finding new treatments for eye disorders.
Stuart Therapeutics' presence at these upcoming meetings demonstrates their dedication to innovation and their potential to make a significant impact in the field of ophthalmology. With their cutting-edge research and promising results, they are poised to become a leader in developing therapies for anterior segment, refractive, and posterior segment eye disorders.
On Friday, May 3rd, Schlumpf will be speaking at the Dry Horizons Symposium, co-sponsored by Ora, Inc. His presentation will focus on Stuart Therapeutics' innovative dry eye disease program, which is currently in a Phase 3 trial. The following day, Saturday May 4th, he will be presenting the company's latest pre-clinical results in retinitis pigmentosa and exudative retinal indications at the Ophthalmology Innovation Source (OIS) Retina Meeting.
Both of these meetings will take place at the Four Seasons Hotel in Seattle, Washington. This provides an opportunity for Stuart Therapeutics to showcase their groundbreaking research to a wide audience of industry professionals.
More on Washingtoner
- MTV EMA Nominee and WOA Founder Oliver Sean Conferred Doctor of Musical Arts (DMA) Degree
- Spokane Police Arrest a Hospice Facility Caretaker
- Tacoma: Homicide Investigation – 400 block of S J St
- Spokane police investigate a stabbing in the area of Thorpe & Westwood
- City of Tacoma Modernizes Access to Municipal Code Online
In addition to Schlumpf's presentations, members of Stuart Therapeutics' R&D team have also co-authored a poster presentation that will be presented by researchers from the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting from May 5-9, 2024. The poster presentation titled "Scleral collagen remodeling and repair assessed in intact eyes through Second Harmonic Generation" focuses on work done at the University of Rochester using Stuart Therapeutics' proprietary collagen mimetic peptide platform. This research aims to understand its effectiveness in reversing scleral collagen disruption in the eye, which is believed to contribute to myopia.
The study authors include Aldo Tecse, Kaitlin Wozniak, James German, Alex McMullen, Mark Buckley, Robert Baratta, Eric Schlumpf, Brian J. Del Buono, Michael Telias and Susana Marcos. This collaboration between Stuart Therapeutics and the University of Rochester highlights the company's commitment to advancing the field of ophthalmology and finding new treatments for eye disorders.
Stuart Therapeutics' presence at these upcoming meetings demonstrates their dedication to innovation and their potential to make a significant impact in the field of ophthalmology. With their cutting-edge research and promising results, they are poised to become a leader in developing therapies for anterior segment, refractive, and posterior segment eye disorders.
0 Comments
Latest on Washingtoner
- Food Journal Magazine Unveils Its Latest 'Best of Los Angeles' Culinary Discoveries
- Boston Industrial Solutions Launches Natron® 717S Series: A New Flexible UV LED Ink for Ricoh GH2220 Printheads
- 5 Things NYC Courier Services Won't Tell You About How Same-Day Delivery Actually Works
- Spokane City Council Votes in Support of Moving Forward the STA Ballot Initiative
- Tropidelic Links Up With International Reggae Star Collie Buddz and Eli Mac for Feel-Good Breakthrough Single "Follow Your Nature"
- Save 15 Percent on Florida Keys Accommodations with KeysCaribbean's 'Advance Purchase Rate Discount'
- Atelier 411 Studios and Columbus Fashion Council Present Red Carpet Experience at Gateway Film Center for The Devil Wears Prada 2
- Hazel E Celebrates Birthday with Luxury "Goddess" Yacht Experience in Marina del Rey
- Joseph Neibich sits down with Bold Jounrey (aka Joseph Nybyk)
- AI Suite 360 Launches Done-For-You AI Implementation to Rescue SMBs from the "Frankenstein Tax"
- Spokane: Mayor Brown Reestablishes City Arts Office, Names New Manager to Lead Effort
- CX Network Releases Report on the Best AI Support Tools for SaaS Companies 2026
- Outlier Pest Season Hits Willamette Valley as Mild Winter Drives Early Surge in Ant and Rodent Activity
- Lokal Media House Wins Web Excellence Award for Black Plumbing Redesign
- Lick Expands Flavored Massage Oil Collection with 10 New Indulgent Cream-Inspired Scents
- New Research Identifies "Vacation Compatibility Gap" as the Hidden Force Shrinking How Long and With Whom Americans Travel
- Melospeech Inc. Awarded New NYSDOH BEI Contract in New York
- Five-star Review for Berklee School of Music Textbook
- One Phone Call Is All It Takes to Lose a New Dental Patient — Here Is Why
- Spokane: Wildfire Evacuation Drill Planned for Latah/Hangman Neighborhood